The Journal of Allergy and Clinical Immunology: In Practice
Review and Feature ArticleAdverse Events and Safety of SARS-CoV-2 Vaccines: What’s New and What’s Next
Key words
Abbreviations used
Cited by (0)
E.J.P. reports grants from the National Institutes of Health (grant nos. P50GM115305, R01HG010863, R01AI152183, R21AI139021, and U01AI154659) and from the National Health and Medical Research Council of Australia. Funders played no role in any aspect of this review.
Conflicts of interest: E. J. Phillips reports grants from the National Institutes of Health (grant nos. P50GM115305, R01HG010863, R01AI152183, R21AI139021, and U01AI154659) and from the National Health and Medical Research Council of Australia; reports royalties from UpToDate and consulting fees from Janssen, Vertex, Biocryst, and Regeneron; is codirector of IIID Pty Ltd, which holds a patent for HLA- B∗57:01 testing for abacavir hypersensitivity; and has a patent pending for Detection of Human Leukocyte Antigen-A∗32:01 in connection with Diagnosing Drug Reaction with Eosinophilia and Systemic Symptoms without any financial remuneration and not directly related to the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.
The case described in this review is a representative patient based on experiences in our outpatient clinic and does not correspond to an actual patient.